About us   Products   News archive   Sitemap   Links   Contact us  

    

Gucci Belt Gold Gg

Gucci Belt Gold Gg

Gucci Belt Gold Gg

Gucci Belt Gold Gg

Gucci Belt Gold Gg

that has demonstrated activity in randomized, double blind, placebo controlled Phase II studies in non small cell lung cancer and in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non small cell lung cancer, and a Phase II/III trial with talactoferrin in severe sepsis is underway. Other clinical development programs include RGB 286638, a multi targeted kinase inhibitor in Phase I testing, and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at

Gucci Belt Gold Gg

Gucci Belt Gold Gg

Gucci Belt Gold Gg

PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX (Marketwire August 10, 2011) Agennix AG (FRANKFURT: AGX) (XETRA: AGX) today announced that the European Patent Office has issued patent number 1507554, entitled, "Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases," covering the use of oral human lactoferrins, including talactoferrin, to treat cancer. It also covers the use of talactoferrin in combination with other therapies, including chemotherapy, immunotherapy, radiation therapy and other treatments. The patent has a term until 2023. This European patent provides broad protection for talactoferrin in this key market, as it covers the use of human lactoferrin for oral administration, used alone or in combination with other therapies, for the treatment of all cancer types. and Japan, two of the other major markets for talactoferrin, that provide protection until 2025 and 2023, respectively, and include coverage for our lead indication, non small cell lung cancer."Talactoferrin is an oral immunotherapy that is being studied for the treatment of cancer and severe sepsis. Talactoferrin has demonstrated promising activity in randomized, double blind, placebo controlled Phase II studies in non small cell lung cancer (NSCLC) and in severe sepsis. Two Phase Hermes Belt For Womens

Gucci Belt Gold Gg

patients whose disease has progressed following two or more prior treatment regimens. A second Phase III trial FORTIS C is evaluating talactoferrin in combination with the standard chemotherapy regimen, carboplatin/paclitaxel, in first line NSCLC patients. NSCLC is one of the most common types of cancer worldwide and the most frequent cause of cancer death. Agennix is also developing talactoferrin Gucci Belt Gold Gg for the treatment of severe sepsis and has initiated a Phase II/III trial, called the OASIS trial, in that indication. The Company's most advanced program is talactoferrin, an oral immunotherapy Gucci Belt Authentic

III trials with talactoferrin in NSCLC are ongoing. The FORTIS M trial, which completed enrollment in March 2011, is evaluating talactoferrin in NSCLC Gucci Belt Gg Buckle

Agennix AG Announces Issuance of European Patent Covering Use of Talactoferrin to Treat Cancer

Gucci Belt Gold Gg

Gucci Belt Gold Gg

Gucci Belt Gold Gg

Gucci Belt High Quality Replica

Hermes Belt Blue

Gucci Belt Double G

Mk Bags Black
Louis Vuitton Belt Monogram

Hermes Belt Black Buckle

Ferragamo Belt On Pants

Hermes Belt New Collection

Michael Kors Clutch Blue
Michael Kors Handbag Outlet
Michael Kors Purses Ebay
Hermes Belt Black And Brown Reversible

Gucci Belt Ebay Uk

Gucci Belt Pics

Michael Kors Handbag Purple

Home / Gucci Belt Gold Gg